Related Experiment Video
Updated: Mar 22, 2026

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
Published on: June 14, 2016
Circulating Antiangiogenic Factors and Myocardial Dysfunction in Hypertensive Disorders of Pregnancy
Sajid Shahul1, Diego Medvedofsky2, Julia B Wenger2
1From the Department of Anesthesia and Critical Care (S.S., J.N., A.T.), Section of Cardiology, Department of Medicine (D.M., R.M.L.), and Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology (S.R.), University of Chicago, IL; Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston (J.B.W., R.T.); Center for Humanizing Critical Care, Intermountain Healthcare, Department of Medicine, University of Utah, Salt Lake City (S.M.B.); Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, Boston, MA (S.B., S.A.K., S.R.); Center for Vascular Biology, Department of Medicine (S.S., S.A.K.) and Department of Anesthesia, Critical Care and Pain Medicine (A.M., D.T.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; and Department of Medicine, Cardiovascular Institute, University of Pennsylvania, Philadelphia (Z.A.). sshahul1@dacc.uchicago.edu.
Abstract:
Hypertensive disorders of pregnancy (HDP) are associated with subclinical changes in cardiac function. Although the mechanism underlying this finding is unknown, elevated levels of soluble antiangiogenic proteins such as soluble fms-like tyrosine kinase-1 (sFlt1) and soluble endoglin (sEng) are associated with myocardial dysfunction and may play a role. We hypothesized that these antiangiogenic proteins may contribute to the development of cardiac dysfunction in HDP. We prospectively studied 207 pregnant women with HDP and nonhypertensive controls and evaluated whether changes in global longitudinal strain (GLS) observed on echocardiography is specific for HDP and whether these changes correlate with HDP biomarkers, sFlt1 and sEng. A total of 62 (30%) patients were diagnosed with preeclampsia (group A), 105 (51%) did not have an HDP (group B), and 40 (19%) were diagnosed with chronic or gestational hypertension (group C). Blood was drawn and sFlt1 and sEng levels measured using enzyme-linked immunosorbent assay. Comprehensive echocardiograms, including measurement of GLS, were performed on all patients. Overall, GLS was worse in women in group A (preeclampsia) than those in group B or C. Increasing sFlt1 and sEng levels correlated with worsening GLS (r=0.44 for sFlt1 and r=0.46 for sEng, both P<0.001), which remained significant after multivariable analysis (r=0.18 and r=0.22, both P≤0.01). Increasing levels also correlated with increasing left ventricular mass index, which also remained significant after multivariable analysis (r=0.20 for sFlt1 and 0.19 for sEng, both P=0.01). Elevated circulating levels of antiangiogenic proteins in HDP correlate with and may contribute to myocardial dysfunction as measured by GLS.
More Related Videos
Related Concept Videos
Hormonal Regulation
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Regulation of Angiogenesis and Blood Supply
Heart Failure II: Pathophysiology
Hypertension II: Pathophysiology
Pathophysiology of Heart Failure

